Cotización Zura Bio - ZURA

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

3.1697

Postura de Compra

3.12

Postura de Venta

3.93

Volume Operado de la Acción

391,789

3.145 Rango del Día 3.72

2.00 Rango de 52 semanas 6.35

Capitalización de Mercado [m]

206.961M

Precio Anterior

3.60

Precio de Apertura

3.72

Hora

3.22

Última hora de negociación

Volumen financiero

US$ 1,314,880

Precio Promedio Ponderado

3.3561

Volumen promedio (3 m)

451,246

Acciones en circulación

65,293,530

Rendimiento del Dividendo

Ratio Precio/Utilidad

-2.99

Beneficio por acción (BPA)

-1.06

turnover

Beneficio neto

-69.24M

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutrali... Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. Mostrar más

Sector

Lab Analytical Instruments

Industria

Blank Checks

Sitio web

zurabio.com

Sede

Grand Cayman, Cym

Fundado

2023

Zura Bio Ltd is listed in the Lab Analytical Instruments sector of the NASDAQ with ticker ZURA. The last closing price for Zura Bio was US$3.60. Over the last year, Zura Bio shares have traded in a share price range of US$ 2.00 to US$ 6.35.

Zura Bio currently has 65,293,530 shares in issue. The market capitalisation of Zura Bio is US$235.06 million. Zura Bio has a price to earnings ratio (PE ratio) of -2.99.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-1.3803	-30.3362637363	4.55	4.85	3.1697	380326	4.21550464	CS
4	-1.7203	-35.1799591002	4.89	5.07	3.1697	336636	4.44856543	CS
12	-0.4203	-11.7075208914	3.59	5.07	3.1697	451246	4.24198461	CS
26	-2.0603	-39.3938814532	5.23	6.35	3.14	360155	4.09691082	CS
52	-1.1603	-26.7967667436	4.33	6.35	2	308131	3.86518352	CS
156	-4.8303	-60.37875	8	37.55	2	342800	6.56819806	CS
260	-4.8303	-60.37875	8	37.55	2	342800	6.56819806	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
CEROCERo Therapeutics Holdings Inc	US$ 0.2853 (52.40%)	1.17B
CYCNCyclerion Therapeutics Inc	US$ 2.5306 (42.97%)	11.99M
SPPLSIMPPLE Ltd	US$ 1.2503 (41.60%)	165.69M
PULMPulmatrix Inc	US$ 6.5586 (39.54%)	5.37M
ZTEKZentek Ltd	US$ 1.2574 (29.96%)	309.67k
TFFPTFF Pharmaceuticals Inc	US$ 0.376101 (-76.49%)	9.35M
EYENEyenovia Inc	US$ 0.10185 (-70.05%)	52.8M
CTXRCitius Pharmaceuticals Inc	US$ 0.1974 (-39.89%)	11.26M
VVPRVivoPower International PLC	US$ 0.8151 (-39.62%)	2.34M
IPWiPower Inc	US$ 0.7302 (-39.15%)	1.15M
CEROCERo Therapeutics Holdings Inc	US$ 0.2853 (52.40%)	1.15B
ELABElevai Labs Inc	US$ 0.0211 (-19.47%)	377.69M
NVDANVIDIA Corporation	US$ 141.98 (-3.26%)	244.07M
SPPLSIMPPLE Ltd	US$ 1.2503 (41.60%)	164.49M
STISolidion Technology Inc	US$ 0.44 (25.71%)	139.46M